Search
Dicoumarol
go.drugbank.com/drugs/DB00266ApprovedIn addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigationalFitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety. … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.
Telavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalTelavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. … MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
iCo-007
go.drugbank.com/drugs/DB05268Investigational) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR). … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
ACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington … ACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases.
Tisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalTisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric … Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia.
Verteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin, marketed as Visudyne, is a benzoporphyrin derivative comprising a 50:50 mixture of two isomers: [CL-315555] and [CL-315585]. … It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration.
Erythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalvarious clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. … The biosimilar is approved by the FDA and EMA as a safe, effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product [A7504].
Products: EXETIN-A, EPO STADA 2000IU/0.6ml Solution for Injection in a Pre-filled SyringeLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigationalLanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells.
1,2-dichlorobenzene
go.drugbank.com/drugs/DB13963ApprovedWithdrawnan insecticide and as an agent to remove carbon-based contamination from metal. … This derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as
Categories: Compounds used in a research, industrial, or household setting